EMA Authorised: Jubereq (denosumab) — Accord Healthcare S.L.U.

View source ↗

Summary

EMA authorised Jubereq (denosumab) from Accord Healthcare S.L.U. for the treatment of Giant cell tumor of bone and other bone neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Bone

Drugs mentioned

• Jubereq (denosumab)

Snippet

Status: Authorised. Therapeutic area: Neoplasms, Bone Tissue;Giant Cell Tumor of Bone. MAH: Accord Healthcare S.L.U.. Decision date: 26/05/2025